SCHEMBL1781029

SCHEMBL1781029

CCOC(=O)C1=C(C)CC(C)CC1=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 6/20 0.38
HTT P42858 1/20 0.38
TSHR P16473 4/20 0.38
MAPT P10636 5/20 0.37
GAA P10253 3/20 0.37
ALOX15 P16050 2/20 0.37
HSD17B10 Q99714 2/20 0.37
HPGD P15428 1/20 0.37
ALOX12 P18054 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 4/20 0.35
TDP1 Q9NUW8 1/20 0.35
ESR1 P03372 1/20 0.35
NR4A1 P22736 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1136326 0.74 SMN1; SMN2 (0.38) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL27711341 0.70 ALDH1A1 (0.36) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL1779388 0.70 ALDH1A1 (0.39) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL15760940 0.69 ALDH1A1 (0.42) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL9626490 0.68 ALDH1A1 (0.49) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL23553548 0.68 NPC1 (0.52) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL6773129 0.68 KMT2A (0.43) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL15328780 0.68 BRD4 (0.63) LMNAALDH1A1HTTTSHRMAPT
SCHEMBL10887883 0.68 CTDSP1 (0.38) KDM4ELMNAALDH1A1HTTTSHR
SCHEMBL21597732 0.66 ALDH1A1 (0.58) KDM4EALDH1A1TSHRMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507559-B2 Cyclohexenyl modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-13 US disclosed
EP-2318352-B1 CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2012-12-19 EP disclosed
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
EP-2318352-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-05-11 EP disclosed
WO-2010009068-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 KDM4E 3489/4885LMNA 4836/4885ALDH1A1 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.